Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference

Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016

BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from single-drop volumes of fluid, today announced the acceptance of four of its scientific abstracts for the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

“We’re looking forward to presenting and publishing this new research, which demonstrates the clinical validity of our assays using just microliters of blood or other bodily fluids,” said Circulogene Chief Scientific Officer Chen-Hsiung Yeh, Ph.D. “Our test’s ability to provide highly sensitive and specific information on cancer gene mutation analysis that can impact personalized treatment decision making continues to greatly interest the medical community.”

The four abstracts accepted include the poster presentation “Circulating cell-free DNA: The future of personalized medicine in ovarian cancer management.” Abstracts accepted for publication only include:

  • Abstract No. e23189 “Massively parallel sequencing of cell-free DNA enriched from a single drop of urine”
  • Abstract No. e13108 “Correlation of mutation status between tissue and blood-drop liquid biopsies from ovarian cancer patients following chemotherapy”
  • Abstract No. e16579 “Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma”

Full-text versions of the publish-only abstracts are available on www.asco.org and jco.ascopubs.org in a fully searchable format.

“We are excited to collaborate with Circulogene and use their liquid biopsy DNA enrichment method and Next Generation Sequencing technique for this ground-breaking research looking at the correlation between tissue and blood biopsies in both pre- and post-chemotherapy in ovarian cancer patients,” said Rebecca C. Arend, M.D., Assistant Professor, University of Alabama – Birmingham.

Circulogene representatives will be on-hand during the conference at booth No. 13104 to answer questions about the science presented and the company’s pioneering work in liquid biopsy development.

Circulogene continues to collaborate with other biotechnology research institutions on additional research projects. Circulogene is the first and only biotechnology company able to enrich circulating cell-free DNA from a single blood drop for patient-specific monitoring of cancer, achieving maximal output from minimal input. The company currently provides testing for breast, colorectal, lung, gastric, gastrointestinal stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid cancers.

Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified and is continuing research initiatives to independently demonstrate greatly increased sensitivity and specificity compared to current methods. For more information, visit our website, connect with us on  LinkedIn, email us at info@circulogene.com or call 855-614-7083.

###

About Circulogene Theranostics

Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the first droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit www.circulogene.com or call 855-614-7083.  

Media Contact
Dan Snyders
Armada Medical Marketing
dan@armadamedical.com
303-623-1190 ext. 230

Company Contact
Scott Rezek
srezek@Circulogene.com
205-278-1607